Pharming Group Announces Restructuring to Cut Costs and Boost Growth

An announcement from Pharming Group ( (PHAR) ) is now available.

On October 6, 2025, Pharming Group announced an organizational restructuring aimed at accelerating growth by reducing general and administrative expenses. The restructuring involves a 20% reduction in non-commercial and non-medical staff, primarily in the Netherlands, and is expected to decrease annual G&A expenses by 15% or $10 million. The company anticipates incurring one-time restructuring costs of approximately $7 million in the fourth quarter of 2025. This move is part of Pharming’s strategy to optimize capital allocation and enhance its operational efficiency.

The most recent analyst rating on (PHAR) stock is a Buy with a $37.00 price target. To see the full list of analyst forecasts on Pharming Group stock, see the PHAR Stock Forecast page.

Spark’s Take on PHAR Stock

According to Spark, TipRanks’ AI Analyst, PHAR is a Neutral.

Pharming Group’s overall stock score is driven by strong technical analysis and positive earnings call sentiment, indicating potential growth. However, financial performance challenges, particularly in profitability and valuation, weigh down the score. The company’s stable balance sheet and cash flow improvements provide a foundation for future growth if profitability can be enhanced.

To see Spark’s full report on PHAR stock, click here.

More about Pharming Group

Pharming Group N.V. is a global biopharmaceutical company focused on developing and commercializing innovative medicines for rare, debilitating, and life-threatening diseases. The company offers a portfolio that includes small molecules and biologics, with its headquarters in Leiden, the Netherlands, and a significant workforce in the U.S.

Average Trading Volume: 11,226

Technical Sentiment Signal: Buy

Current Market Cap: $1.11B

See more insights into PHAR stock on TipRanks’ Stock Analysis page.